本帖最后由 老马 于 2012-1-13 21:20 编辑
9 R; l6 z! A& V( d1 c3 Z5 Q" f9 o, `& A# ~% g( K$ u* {8 h
爱必妥和阿瓦斯丁的比较
8 ?+ l4 {$ s. S# a
: E5 [. B' U! }' r% fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
6 Z' U2 N7 Y5 }5 x7 @4 ^
3 d: A# j; D6 @) Q+ @6 s; E6 F
9 L# C3 l% _7 ~- p8 b5 }http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ F% g5 X: b! W# j `
==================================================
l, x c- T* Y hOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 H4 P; E" j# W" l6 M
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ T7 [5 B7 }2 a. E' }. W
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 \4 u, v6 r' e, t4 G; B) ]$ z( h' L
|
显身卡
